OR WAIT 15 SECS
Dentists must take responsibility for monitoring the oral mucosa of their patients, Dr. Mark Lingen said at the ADAâ€™s 2016 meeting.
Squamous cell carcinoma (SCC) is the 6th most common malignancy in the world. Classical SCC carries a 5-year survival rate of approximately 55%. As described by Dr. Mark Lingen, DDS, PhD, at the ADA’s 2016 meeting in Denver, CO, the treatment plan for SCC must include early detection and improved modalities for prognostication and prevention, affording the greatest chance of survival for the patient. Dr. Lingen gave his presentation on Thursday, October 20 at the conference.
Performing patient screening is the backbone of early detection, Dr. Lingen said. Screening tests are not diagnostic tools, however. Additionally, oral cancer screening is not a stand-alone test. It is part of the dentist’s comprehensive exam, including both visual and physical or tactile components, used to identify any abnormalities or pathologies of the oral and/or maxillofacial region. A typical medical education does not teach comprehensive oral pathology. It is left to dentist to take sole responsibility for monitoring the oral mucosa of his/her patients.
The table below highlights additional methods currently available to assist in detection of oral cancers. All methods listed are to be used in conjunction with the visual/physical exam. The devices below are “cleared for marketing” via the FDA 501(k) program. This program is for noninvasive devices and requires the device to demonstrate safety, but does not establish efficacy.
Brush Cytology (scrape cells from mucosa, place on a slide, send out for analyzation)
Tissue Reflectance (Patient rinse with acetic acid, use light to evaluate lesions)
Tissue Autofluorescence (wavelength of light shone into mouth, looking for loss of autofluorescence)
Reflectance and Autofluorescence (combination of the two individual components)
Salivary Diagnostics- HPV (saliva based HPV testing)
Salivary Diagnostics- Other (genetic markers, RNA/DNA, or proteins in the saliva)
A note about HPV
Oral cavity SCC (OSCC) is secondary to chronic exposure of tobacco and alcohol. While the epidemic of oropharyngeal SCC is secondary to HPV-16. According to the CDC, one percent of the population has HPV-16 in their saliva. However, only 35,000 new cases of HPV associated malignancy occur each year. This is because upward of 95% of infections are cleared from the body. Therefore, screening is rather tricky. The concern with the salivary diagnostic tests for HPV, is the interpretation of a positive test. As of now, the understanding of the natural history of HPV is low. More clinical data is needed to help guide dentists in the use of HPV salivary diagnostic tests.
There are a multitude of adjunctive therapies available to dentists to help screen and prevent progression of oral cancers. The dentist will need to clinically evaluate whether or not a test/device will help to determine the clinical course of action for his/her patient. The point to be stressed however, is that no matter the modality, early detection and prevention of oral cancers is key to patient survival.